Gastrointestinal toxicities secondary to immune checkpoint inhibitors are very frequent. Because in some instances this can be severe or fatal, it is essential to be able to identify immune-related adverse events rapidly. Prompt initiation of systemic immunosuppression can improve outcomes. A biopsy is often necessary to confirm the diagnosis of immune-related adverse events. Moderate or severe irAEs need an interruption of ICI. After the resolution of the toxicities, the rechallenge of immune checkpoint inhibitors must be discussed case by case.
Keywords: Colitis; Hepatitis; Immuncheckpoint-Inhibitoren Toxizitäten; Immune checkpoint inhibitors; Inhibiteurs de point de contrôle immunitaire; Management; colite; colitis; hepatitis; hépatite; management; prise en charge; toxicities; toxicités.